Ovid Therapeutics (OVID) PT Set at $10.00 by Cantor Fitzgerald
A number of other research analysts also recently issued reports on the company. Zacks Investment Research upgraded Ovid Therapeutics from a hold rating to a buy rating and set a $7.25 price objective for the company in a research note on Tuesday, September 4th. ValuEngine downgraded Ovid Therapeutics from a hold rating to a sell rating in a research note on Thursday, August 23rd. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $15.69.
Shares of Ovid Therapeutics stock opened at $2.99 on Monday. Ovid Therapeutics has a 12-month low of $2.93 and a 12-month high of $11.45. The firm has a market cap of $73.96 million, a P/E ratio of -0.89 and a beta of 1.03.
A number of large investors have recently made changes to their positions in OVID. JPMorgan Chase & Co. grew its stake in Ovid Therapeutics by 136.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 54,832 shares of the company’s stock valued at $311,000 after purchasing an additional 31,687 shares during the period. Dimensional Fund Advisors LP bought a new position in Ovid Therapeutics in the 3rd quarter valued at $444,000. Northern Trust Corp grew its stake in Ovid Therapeutics by 9.3% in the 2nd quarter. Northern Trust Corp now owns 129,497 shares of the company’s stock valued at $1,010,000 after purchasing an additional 11,067 shares during the period. Redmile Group LLC grew its stake in Ovid Therapeutics by 498.7% in the 3rd quarter. Redmile Group LLC now owns 730,150 shares of the company’s stock valued at $4,140,000 after purchasing an additional 608,200 shares during the period. Finally, Cowen Inc. bought a new position in Ovid Therapeutics in the 2nd quarter valued at $5,169,000. Hedge funds and other institutional investors own 29.98% of the company’s stock.
About Ovid Therapeutics
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
Read More: What is a Market Correction?
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.